Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
clinical trials
fda
life sciences
national blog main
san francisco blog main
san francisco top stories
boston blog main
boston top stories
europe blog main
europe top stories
national
national top stories
abaloparatide
amgen
arena pharmaceuticals
avapritinib
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
cancer
cardiovascular disease
colorectal cancer
cstone pharmaceuticals
deals
detroit blog main
detroit top stories
eisai
eli lilly
european commission
european medicines agency
fisogatinib
flatiron health
genentech
hepatocellular carcinoma
indiana blog main
indiana top stories
investing
jeff albers
What
drug
marketing
3
×
approval
cancer
fda
medicine
wins
amgen
amgen’s
blueprint
candidate
carries
currently
developed
eisai
europe
european
flags
heart
higher
incidence
lorcaserin
loss
market
medicines
muscle
nod
osteoporosis
pact
patients
post
pulls
raise
regulatory
ret
review
risk
risks
roche
study
Language
unset
Current search:
marketing
×
biotech
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning